GMO Gamecenter USA, Inc. v. Whinstone US, Inc.

District Court, S.D. New York·Decided July 17, 2025·No. 1:22-cv-05974·Unknown

Opinion

an vvninstone snail respond to ge USDC SDNY this letter by Monday, July DOCUMENT 21, 2025. ELECTRONICALLY FILED July 16, 2025 DOC #: SO ORDERED: 07/17/2025 DATE FILED: 071172025 ly. Veta guise + ber en ee HON. KATHARINE H. PARKER New York, NY 10007 UNITED STATES MAGISTRATE JUDGE Re: GMO Gamecenter USA, Inc., et al. v. Whinstone US, Inc., No. 1:22-cv-05974 Dear Judge Parker: Pursuant to the Court’s instruction at the June 16, 2025 conference, Plaintiffs GMO Gamecenter USA Inc. and GMO Internet, Inc. (collectively, “GMO”) respectfully submit this letter request for a stay of the deposition of Masatoshi Kumagai while GMO’s Rule 72 Objection to the May 23, 2025 Order denying GMO’s motion for a protective order (ECF No. 388, the “Objection”) remains pending before Judge Cronan. On May 23, 2025, this Court denied GMO’s motion for a protective order, which sought to prevent the apex deposition of Mr. Kumagai, GMO’s CEO. ECF No. 367. On June 6, GMO filed its Objection with Judge Cronan, requesting that GMO’s motion for a protective order be granted and that Mr. Kumagai be relieved of the burden of his apex deposition. ECF No. 388. At the June 16 status conference, GMO requested a stay of the Kumagai deposition while the Objection is pending, and the Court instructed GMO to request a stay within 30 days. See ECF No. 408, June 16 Tr. at 8:2-15. GMO now makes its stay request. Courts in this District have held that “[flour factors guide a court’s exercise of [its] discretion” to stay a discovery order pending a Rule 72 objection: “(1) whether the stay applicant has made a strong showing that [they are] likely to succeed on the merits; (2) whether the applicant will be irreparably injured absent a stay; (3) whether the issuance of the stay will substantially injure the other parties interested in the proceeding; and (4) where the public interest lies.” Monterey Bay Mil. Hous., LLC v. Ambac Assurance Corp., No. 19-cv-9193, 2023 WL 5498962, at *4 (S.D.N.Y. Aug. 25, 2023) (quoting Nken v. Holder, 556 U.S. 418, 433 (2009)). Other courts in this District have held that a party seeking such a stay must demonstrate “good cause,” Thai Lao Lignite (Thailand) Co. v. Govt of Lao People’s Democratic Republic, 924 F. Supp. 2d 508 (S.D.N.Y. 2013), which standard balances “the breadth of discovery sought, the burden of responding to it, the prejudice that would result to the party opposing the stay, and the strength of the pending motion forming the basis of the request for stay.” Brawer v. Egan-Jones Ratings Co., 348 F.R.D. 182, 185 (S.D.N.Y. 2025). GMO addresses these overlapping standards in turn. 1. Without a Stay, GMO Would Be Irreparably Harmed Given the Burden and Breadth of the Requested Apex Deposition Subject to the Pending Objection. If this Court does not stay Mr. Kumagai’s apex deposition, GMO’s pending Objection will be rendered moot, since it would be forced to proceed with the deposition despite the possibility that its Objection is granted. Mr. Kumagai’s deposition would create an immense and unretractable burden on GMO (and a lesser but substantial burden on Whinstone, for that matter) that may not be necessary after Judge Cronan rules on the Objection.

HAYNES BOONE □□ The Court’s May 23 Order correctly recognized that Mr. Kumagai is an apex executive and as such, “there 1s a rebuttable presumption that [his] deposition represents an undue burden.” ECF No. 367 at 2; Gen. Star Indem. Co. v. Platinum Indem. Ltd., 210 F.R.D. 80, 83 (S.D.N.Y. 2002) (because of the “possibility of harassment and the potential disruption of business” courts can “deny a request to depose a high ranking corporate official when lower ranking executives have access to the same information.”); United States ex rel. Galmines v. Novartis Pharms. Corp., No. 06-cv-3213, 2015 WL 4973626, at *1 (E.D. Pa. Aug. 19, 2015) (The apex doctrine “recognizes that depositions of high-level officers severely burden those officers and the entities they represent, and that adversaries might use this severe burden to their unfair advantage.”). Indeed, Mr. Kumagai’s apex deposition would subject GMO to a significant burden and expense that could never be undone. While any deposition of Mr. Kumagai would severely disrupt GMO’s business due to the amount of preparation, travel, and deposition time required, Whinstone’s (latest) request to depose Mr. Kumagai in New York for 14 hours, if granted, could prevent Mr. Kumagai from leading GMO for days, if not a full week. The deposition would also subject GMO and Whinstone to significant legal fees for counsel’s preparation for and attendance at the deposition. There is no need to impose such an immense burden on GMO, when Judge Cronan may grant the Objection and dispense with the deposition altogether. Amron v. 3M Minnesota Mining & Mfg. Co., No. 23- cv-08959, 2024 WL 263010, at *3 (E.D.N.Y. Jan. 24, 2024) (stay of discovery warranted “because the parties could avoid substantial burden and waste of precious resources by staying discovery”). 2. GMO is Likely to Succeed on its Objection. Mr. Kumagai should not be subject to an apex deposition given the high legal standard for such discovery and because he does not have unique, relevant knowledge. See ECF No. 367 at 2 (May 23 Order holding that “unless an executive ‘has unique evidence, personal knowledge of the claims at issue,’ and ‘other witnesses are incapable of providing testimony about the conduct alleged, executives are protected from being deposed,’” citing cases). Specifically, and as explained in detail in GMO’s Objection, the evidence shows that (1) other (already deposed) GMO employees share Mr. Kumagai’s relevant knowledge, and (2) Mr. Kumagai’s mere signing of the Texas Agreement does not demonstrate unique, relevant knowledge because he signed in a representative capacity and was not involved in its negotiation. See ECF No. 388 at 12-21; Invs. Ins. Co. of Am. v. Dorinco Reinsurance Co., 917 F.2d 100, 105 (2d Cir. 1990) (“Browne’s testimony, however, provides only limited evidence of Investors’ intent, as Browne was not a primary participant in the negotiations between Investors and Dorinco.”). GMO’s Objection alternatively seeks a ruling that Mr. Kumagai’s deposition (1) be limited to two hours in duration on specified areas of inquiry (if any) where the Court finds that Mr. Kumagai has unique knowledge on important issues and (2) take place at the U.S. Consulate in Tokyo. ECF No. 388 at 25. Since the Court’s May 23 Order, Whinstone has made clear its intent to use the deposition solely to harass GMO and Mr. Kumagai. Whinstone initially represented to this Court (before Mr. Kumagai’s deposition was ordered) that it was “willing to hold his deposition . . . at the consulate in Japan if available (or another location in Asia) if Mr. Kumagai would prefer.” ECF No. 361 at 21. Yet after GMO provided Whinstone with dates on which the consulate was available, Whinstone changed its mind, arguing that the deposition should occur in New York because a deposition in Japan would be inconvenient, despite Whinstone’s counsel having an office in Tokyo. ECF No. 404 at 23. Whinstone also has made no effort to book Mr. Kumagai’s available dates at the U.S. Consulate in Tokyo. That is because Whinstone does not

HAYNES BOONE □□ actually need the deposition, and instead only wants to harass GMO’s highest-ranking executive. Consol. Rail Corp. v. Primary Indus. Corp., No. 1:92-cv-4927, 1993 WL 364471, at *1 (S.D.N-Y. Sept. 10, 1993) (“[P]ermitting unfettered discovery of corporate executives would threaten disruption of their business and could serve as a potent tool for harassment in litigation.”).

Free access — add to your briefcase to read the full text and ask questions with AI

GMO Gamecenter USA, Inc. v. Whinstone US, Inc., (S.D.N.Y. 2025).

GMO Gamecenter USA, Inc. v. Whinstone US, Inc. (GMO Gamecenter USA, Inc. v. Whinstone US, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related